42 results about "Hypertrophic scars" patented technology

The scar removing cream is prepared from the following raw materials in percentage by weight: 30 to 80 percent of silica gel component, 5 to 30 percent of solvent, 0.1 to 10 percent of emulsifying agent, 1 to 5 percent of thickening agent, 0.01 to 10 percent of extract / synergistic component, 0.1 to 20 percent of medicament component, 1 to 50 percent of moisturizing component, 0.01 to 0.1 percent of growth factor, 0.1 to 2 percent of other component, 0.01 to 0.5 percent of preservative and 0.1 to 2 percent of pH (Potential of Hydrogen) regulator. The traditional Chinese medicine composition has the effects of improving skin repair, whitening and diminishing inflammation, accelerates skin elasticity recovery and reduces scars.

The embodiment of the invention provides a self-powered microneedle patch for repairing hypertrophic scars as well as a preparation method and application of the self-powered microneedle patch. The self-powered microneedle patch comprises: a friction nano-generator for generating a current; the conductive drug-loaded microneedle patch is connected with the friction nano-generator, and the friction nano-generator is connected with the conductive drug-loaded microneedle patch; the conductive drug-loaded microneedle patch comprises a conductive microneedle patch body and a crosslinked gelatin-crosslinked hyaluronic acid microneedle bearing Sb4. The surface of the conductive micro-needle patch is provided with a metal coating, and the conductive micro-needle patch is used for mediating current generated by the friction nano-generator and applying percutaneous electrical stimulation; the cross-linked gelatin-cross-linked hyaluronic acid microneedle is coated at the tip of the conductive microneedle patch. According to the self-powered microneedle patch provided by the embodiment of the invention, myofibroblasts of hypertrophic scars are transdifferentiated into adipocytes by providing percutaneous electrochemical stimulation, inflammatory factor release is inhibited, and a tissue microenvironment is remodeled, so that the hypertrophic scars are reversed, and skin repair and tissue regeneration are realized.

Some embodiments are directed to a skin treatment system that contains a laser generating device. A hydrogel patch may include a region, at a first side of the hydrogel patch, to be in contact with a person's skin. The region may contain an adsorbing medium (e.g., carbon black or any other substance that would have a similar effect) that, when receiving a laser beam from the laser generating device, results in Extracorporeal Shock Wave Therapy (“ESWT”) being applied to the person's skin to treat a dermatologic condition such as an epidermal or dermal tissue structure irregularity, cellulite, a stretch mark, a scar, scar-tissue, a hypertrophic scar, an acne scar, etc.

The invention discloses double-network hydrogel based on chlorogenic acid as well as a preparation method and application of the double-network hydrogel, and belongs to the technical field of wound dressings. A first network of the double-network hydrogel based on the chlorogenic acid is formed by coordination of the chlorogenic acid and Zn < 2 + >, and CA and Zn < 2 + > can be quickly released in inflammation and proliferation stages, so that the effects of resisting bacteria, resisting oxidation, diminishing inflammation and generating blood vessels are achieved; the second network is formed by covalent crosslinking of heparin grafted gelatin and genipin, crosslinking of gelatin and genipin can enhance the mechanical strength, heparin is grafted into gelatin, bFGF can be stably added, the release time of bFGF at a wound part can be prolonged, and bFGF is slowly released in proliferation and remodeling stages, so that scars are prevented from being formed; in-vivo studies of MRSA infected diabetic mouse models and rabbit ear hyperplastic scar models show that the dual-network hydrogel can significantly promote healing of scar-free wounds. The programmed release function of the CZGF hydrogel plays a key role in accelerating chronic wound healing and preventing scar formation.

A microneedle loaded with at least curcumin, exosomes, and an acellular matrix. Curcumin is incorporated into the exosomes to form functionalized exosomes (Cur@EV), which serve as the primary active ingredient for the repair of hypertrophic scars. Cur@EV has been shown to exhibit a high affinity for hypertrophic scar fibroblasts, while more efficient delivery of curcumin to HSFs has demonstrated enhanced anti-HSF cell proliferation activity and significant anti-fibrosis effects, potentially meeting clinical needs for the repair of hypertrophic scars.

The present specification discloses a method, system, and apparatus for inhibiting collagen production in fibroblasts using an alternating electric field. In one aspect, the present invention can effectively regulate ECM homeostasis by inhibiting the production of type I procollagen and increasing MMP-1 expression using a low-frequency and low-intensity alternating electric field, thereby effectively regulating (inhibiting) collagen production in fibroblasts. In another aspect, it has the advantage of being applicable not only to the treatment of fibroproliferative skin diseases such as hypertrophic scars and keloids, but also to the prevention and treatment of general surgical wounds that occur after surgery.

The invention discloses an application of an activator combined by one or more genes / proteins in preparation of drugs for treating hypertrophic scars, and belongs to the technical field of biological medicines. In order to solve the problem that when retinoic acid cream is used for preparing hypertrophic scars, a specific mode and an action target of a retinoic acid signal channel for regulating and controlling fibroblasts are not disclosed yet, the action target and a regulation and control mechanism of ATRA for regulating and controlling fibroblast activation and glucose metabolism remodeling are explored through in-vivo and in-vitro experiments; and on the basis of a Cre-loxP system, the function of the target gene is verified. Researches in the invention show that ATRA promotes transcription of HIC1 and inhibits transcription and expression of TGF-beta1 by activating RAR alpha on one hand, and ATRA promotes transcription of HIC1 and inhibits transcription and expression of TGF-beta1 on the other hand; on the other hand, the transcription of PCK1 and PCK2 is promoted, so that the proliferation and abnormal activation of HSFs are reduced, and the occurrence and development processes of hypertrophic scars are finally inhibited. The conclusion provides a sufficient theoretical basis for inhibiting hypertrophic scar formation by ATRA.

The invention discloses a bionic hybrid carrier for actively targeting hypertrophic scars as well as a preparation method and application of the bionic hybrid carrier. According to the preparation method, materials such as scar fibroblast cell membrane protein, a cation carrier and siRNA are adopted, hybridization of a cell membrane and the cation carrier is achieved through an ultrasonic co-extrusion technology, and the carrier is endowed with immune escape and homologous targeting capacity; high-efficiency loading of TGF-beta1 siRNA is realized by utilizing electrostatic self-assembly, so that a bionic transdermal delivery system with an active targeting characteristic is constructed. The bionic hybrid carrier not only provides an innovative thought for root therapy of hypertrophic scars, but also opens up a new way for gene intervention of other skin fibrosis and inflammation related diseases, and has important clinical transformation value.

The invention discloses an adjustable post-burn hypertrophic scar treatment device, relates to the technical field of medical instruments, and provides the following scheme that the adjustable post-burn hypertrophic scar treatment device comprises a bed body, an arch bridge is slidably connected to the bed body, a fixing cylinder is connected to the arch bridge, a fixing shell is rotatably connected to the bottom end of the fixing cylinder, and a fixed air bag is embedded into the bottom end of the fixing shell; the bottom end of the fixing shell is sleeved with a rubber sleeve, the fixing barrel is connected with mesh cloth, a fixing block is installed at the bottom end in the air bag, and the bottom end of the fixing block is slidably connected with a plurality of knocking columns. The air bag is moved to the position above the scar through the arch bridge, the expanded air bag extrudes the scar, in the process of pressurizing the scar, the air bag extrudes the rubber sleeve and the screen cloth to make the rubber sleeve and the screen cloth tightly abut against the surface of the scar and drive the air bag and the rubber sleeve to rotate, and absorption of the scar to liquid medicine is promoted through pressurization and rotating friction of the rubber sleeve; and the knocking column continuously strikes the rubber sleeve, so that the scar softening is promoted.

The application discloses a kind of active targeting hyperplastic scar's biomimetic hybrid delivery vehicle and its preparation method and application.The application uses scar fibroblast membrane protein, cationic delivery vehicle and siRNA and other materials, realizes the hybridization of cell membrane and cationic delivery vehicle by ultrasonic co-extrusion technology, and gives the immune escape and homologous targeting ability of carrier;Efficient loading of TGF-β1 siRNA is realized by using electrostatic self-assembly, so as to construct a biomimetic transdermal delivery system with active targeting characteristics.The biomimetic hybrid delivery vehicle not only provides an innovative approach for the root cause treatment of hyperplastic scar, but also opens up a new way for gene intervention of other skin fibrosis and inflammation-related diseases, and has important clinical translation value.

The application belongs to the field of new use of drugs, and more particularly relates to application of 3-Deazaadenosine in preparation of a therapeutic drug for treating hypertrophic scars. 3-Deazaadenosine is an S-adenosylhomocysteine hydrolase inhibitor, and has antiviral, anti-inflammatory and other activities. Experiments show that the compound can significantly reduce the modification level of m6A in fibroblasts in hypertrophic scar tissue, inhibit the proliferation and migration of fibroblasts, promote the apoptosis of fibroblasts, and also can reduce the expression levels of Collagen I, Collagen III and alpha-SMA in fibroblasts. Therefore, the compound can be used for preparing a drug for relieving or treating hypertrophic scars, and has important clinical application value.

The present invention discloses a supramolecular anti-hypertrophic scar material and its preparation and application, which relates to the technical field of nano-diagnostic and therapeutic materials. The material comprises amphiphilic vesicles formed by the assembly of water-soluble supramolecular macrocycles and hydrophobic Chinese herbal molecules through host-guest interactions, wherein the inner and outer layers of the vesicles are both supramolecular macrocycles, and the hydrophobic Chinese herbal molecules are located between the inner and outer layers of the vesicles; the interior of the amphiphilic vesicles is loaded with enriched metal nanoclusters. The present invention assembles hydrophilic supramolecular macrocycles and active ingredient hydrophobic Chinese herbal molecules into vesicles through supramolecular host-guest interactions, and then loads functional component metal nanoclusters, thereby constructing a high-performance supramolecular material for the treatment of hypertrophic scars based on the ferroptosis-apoptosis synergistic mechanism.

The invention provides multi-effect composite scar repair gel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention develops a multi-effect composite scar repair gel with barrier protection, anti-inflammatory regeneration and long-acting permeation by integrating a silicone base material, traditional Chinese medicine active ingredients and an ionic liquid permeation promotion technology. Wherein the high-viscosity polydimethylsiloxane is used for reducing skin tension; the low-viscosity polydimethylsiloxane improves the skin comfort level; the traditional Chinese medicine extract inhibits fibroblast proliferation and promotes microcirculation; the Ectoin-allantoin microcapsule is capable of realizing 72-hour slow-release anti-inflammatory repair; the BPC157 polypeptide can promote angiogenesis and accelerate wound healing; the transdermal rate of the active ingredients is increased by more than 3 times by the arginine-malic acid ionic liquid; the zinc hyaluronate can synergistically moisturize and regulate the inflammation microenvironment. Through cooperation of multiple mechanisms, the effects of barrier protection, anti-inflammatory regeneration and long-acting permeation are achieved, and the anti-inflammatory and long-acting anti-inflammatory ointment is suitable for repairing hypertrophic scars, acne scars and postoperative incisions.

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition, a pharmaceutical preparation and a preparation method and application thereof, and the traditional Chinese medicine composition comprises the following components in parts by weight: 0.15-0.3 part of blumea balsamifera, 0.15-0.3 part of borneol, 1-3 parts of juncus effuses, 6-10 parts of eucommia ulmoides, 6-10 parts of kelp, 0.1-0.5 part of wormwood essential oil, 4-5 parts of myrrh, 6-10 parts of eclipta, 9-15 parts of muskmelon seed and 4.5-6 parts of gallnut. The traditional Chinese medicine composition provided by the invention can reverse hypertrophic scar key imbalance signal channels and inhibit scar cell proliferation and migration, is high in safety and reliability, and can effectively inhibit scar hyperplasia and improve color, softness and thickness of pathological scars.

The invention relates to the technical field of drugs for treating hypertrophic scars, in particular to application of triglycosyl ceramide in treatment of hypertrophic scars. Based on a newly found molecular regulation mechanism, the heterogeneity of skin fibroblasts is regulated in a targeted manner, so that pathological fibrosis and scar formation in a burn wound healing process are effectively inhibited. The invention provides a strategy for accurately intervening the transdifferentiation of fibroblasts to myofibroblasts and promoting the fibrosis direction. In the prior art, an effective target spot aiming at a fibroblast heterogeneity key regulation and control node on a burn wound surface is lacked. The invention discloses a new'HEXB-Gb3-FGF2 'regulation axis, and develops a treatment method for specifically targeting a key product triglycosyl ceramide of glycosphingolipid metabolism.

The invention discloses comprehensive medical equipment for prevention and adjuvant therapy of scar hyperplasia, and relates to the technical field of medical equipment. Comprising a supporting mechanism and a hyperplasia prevention mechanism, the hyperplasia prevention mechanism is arranged at the top end of the supporting mechanism, the hyperplasia prevention mechanism is used for preventing wound hyperplasia and comprises a mounting frame, the mounting frame is arranged at the top end of the supporting mechanism, and a through groove penetrating through the outer surface is formed in the inner wall of the mounting frame; the top end of the heat-conducting plate is fixedly connected with heat-conducting pipes. By means of the hyperplasia prevention mechanism, a wound can be slightly heated when the device is used, it is ensured that blood circulation can be well promoted when the device is used, it is ensured that local oxygen supply and nutrient supply can be increased, the wound healing process is accelerated, the wound healing duration is shortened, and the wound healing effect is improved. And it is ensured that good practicability can be achieved when the equipment is used, and the convenience of the equipment is improved.

This invention describes methods for treating wound healing pathologies, inhibiting or reversing fibrotic skin disorders, including but not limited to keloids, atrophic and hypertrophic scars, and reversing skin aging via generating new dermal adipocytes (DAs). Methods described herein comprise (a) grafting of human hair follicles or (b) direct delivery of conditioned media from in vitro cultured hair follicles, or (c) delivery of purified individual factors secreted by hair follicles, or (d) delivery of small molecule agonists that mimic hair derived signaling activities, or (e) delivery of small molecule antagonists that inhibit anti-adipogenic programs, or (f) delivery of small molecule agonists of pro-adipogenic programs to convert endogenous wound or scar skin fibroblasts into new DAs.

This invention discloses a combination of biomarkers, a kit, and their applications for detecting hypertrophic scars (HTS). The biomarker combination includes a core biomarker and / or auxiliary biomarker 1 and / or auxiliary biomarker 2; the core biomarker is ABCC9 and CSPG4, auxiliary biomarker 1 is RGS5 and ACTA2, and auxiliary biomarker 2 is PDGFRB and TRPC6. This invention also provides a kit containing the above biomarker combination detection reagents and a drug screening method. This invention reveals for the first time that pathological pericytes are the core fibrotic cells in HTS, breaking through the traditional understanding that fibroblasts are the dominant cells. By targeting and inhibiting the abnormal activation, proliferation, and transdifferentiation of pericytes into myofibroblasts, the generation of myofibroblasts and matrix deposition are curbed at the source, providing a new strategy for precision treatment of HTS. Compared with traditional therapies, this approach has higher specificity and can achieve early molecular warning and quantitative detection of trace tissues for HTS, effectively overcoming the lag and subjectivity of clinical morphological diagnosis.

The method of preparation of biomass to support healing of hypertrophic scars and keloids, contains the steps: Culturing of mycelium of the filamentous fungus, Preparation of a pure culture of the filamentous fungus, Verification of the generic and species affiliation of the filamentous fungus, and Finalization of the biomass. The biomass produced in this way is deposited on a nanotechnology substrate in the form of a foil. Biomass according to this solution is suitable for supporting the healing of hypertrophic scars and keloids or to test medicinal substances intended for the skin.

The invention discloses a double-drug-loading soluble microneedle patch with a hypertrophic scar improving function as well as a preparation method and application of the double-drug-loading soluble microneedle patch, and belongs to the technical field of medical cosmetology. The microneedle patch comprises a substrate and a needle body arranged on the surface of the substrate, wherein the needle body is mainly prepared from a cyclodextrin inclusion compound, colchicine and a microneedle framework material; the cyclodextrin inclusion compound is prepared from an insoluble drug shikonin and beta-cyclodextrin, and the microneedle framework material is prepared from sodium hyaluronate and polyvinylpyrrolidone. The double-drug-loading soluble microneedle patch has good mechanical strength and can accurately penetrate through scar skin to form a drug delivery channel. Compared with a traditional transdermal patch, the soluble microneedle has the advantages that the transdermal permeation efficiency of the medicine is greatly improved, and compared with traditional injection administration, the soluble microneedle reduces long-term irritation to the skin, reduces the risk of adverse reactions such as infection and bleeding and has a very good application prospect.

The invention belongs to the technical field of medicines, and particularly relates to hydrogel for resisting collagen proliferative diseases as well as a preparation method and application of the hydrogel. According to the hydrogel for resisting the collagen proliferative diseases, by optimizing the composition and proportion of the hydrogel, the salvianic acid hydrogel can effectively prevent and treat hypertrophic scars. The salvianic acid hydrogel dosage form provided by the invention is used for local administration, is convenient to operate, and can improve the compliance of patients compared with oral medicines (such as compound salvia miltiorrhiza dropping pills). The salvianic acid hydrogel dosage form can be uniformly smeared on the surface of a wound and quickly forms a film for covering, so that the local concentration of salvianic acid is increased, and a relatively good treatment effect is achieved. And the tanshinol hydrogel dosage form is simple and convenient in production process and low in cost, is an economical and effective treatment scheme, and has a good prospect in prevention or treatment of collagen hyperplasia diseases.

The present invention relates to the technical field of medical dressings, and discloses a scar repair gel containing recombinant mussel mucin and a preparation method thereof. The scar repair gel comprises the following components in percentage by mass: 0.01-0.2% recombinant mussel mucin, 0.4-0.8% thickener, 6-15% compound emulsifier, 1-2% pH adjuster, 20-40% silicone, 0.1-0.3% preservative and the balance of water, wherein the silicone comprises polydimethylsiloxane, polydimethylsiloxane crosslinker and decamethylcyclopentasiloxane. The scar repair gel containing recombinant mussel mucin has good film-forming properties, forms a moisturizing barrier on the surface of the wound, can inhibit the formation of hypertrophic scars, reduce itching during wound healing, reduce the production and deposition of melanin, effectively improve the patient's comfort during use and the stability of the mussel mucin and silicone gel system.

The invention discloses a control method of a microneedle patch for treating hypertrophic scars and related equipment. The method is used for being connected with a controller of the microneedle patch for treating hypertrophic scars. The microneedle patch for treating hypertrophic scars comprises a plurality of heating units and a plurality of microneedles, each microneedle contains a medicine wrapped by a thermal response material, and the heating units are in one-to-one correspondence with the microneedles; according to the method, a first image containing a hypertrophic scar area and a second image formed by pasting a hypertrophic scar treatment microneedle patch on the hypertrophic scar area can be obtained; drawing a target contour of the hypertrophic scar area in the second image based on the first image; determining a target heating unit corresponding to the target contour; and heating each target microneedle by using each target heating unit. Therefore, according to the application, the corresponding microneedle can be accurately positioned and heated according to the specific forms of different hypertrophic scars, so that the customization of the drug release shape is realized, and the problem that the fixed-shape drug release of the traditional microneedle patch is difficult to adapt to different scars is solved.

The invention provides a ciclopirox olamine composite medicine and application thereof in preparation of a medicine for inhibiting scars, and a preparation method of the ciclopirox olamine composite medicine comprises the following steps: S1, preparing a hyaluronic acid solution; and S2, adding the ciclopirox olamine into a hyaluronic acid solution, and carrying out ultrasonic dissolution to obtain the ciclopirox olamine composite medicine. The ciclopirox olamine composite medicine has the effect of inhibiting hypertrophic scars at lower concentration.

The present invention pertains to a cyclic analogue of glycine-proline for use in the prevention and / or treatment of fibrosis, for example skin fibrosis, hypertrophic scars, keloids, organ-specific fibrosis or implant-related fibrosis. The peptide of the invention can be administered orally, but also instance provided in a topical formulation or cosmetic composition. Moreover, the peptide of the invention can be provided as a coating on an implantable device and / or medical device, to prevent excess fibrosis and encapsulation thereof.

The invention discloses a silicone preparation pressure device for treating hypertrophic scars. The silicone preparation pressure device comprises a dressing layer and a negative pressure assembly. The dressing layer comprises a viscous semi-permeable membrane and a silicone dressing layer from outside to inside according to the direction of being fixed on the body surface; the area of the viscous semi-permeable membrane is larger than that of the silicone dressing layer, so that the silicone dressing layer can be completely covered and sealed; a display screen is arranged at the top of the negative pressure assembly, and a negative pressure channel is formed in the bottom of the negative pressure assembly and used for connecting the negative pressure assembly with the viscous semi-permeable membrane; and the negative pressure assembly can extract air in a space formed between the viscous semi-permeable membrane and the skin to form a negative pressure state.

This application relates to the field of diagnostic reagents, specifically to a scar diagnostic reagent and its application. This application is the first to discover CD3+ in the peripheral blood of keloid patients. + CD8 + The study revealed a significant decrease in cytotoxic T cells, highlighting for the first time the crucial role of the immune microenvironment in the pathogenesis of keloids. Furthermore, it was the first time that sHLA-E expression was significantly different in normal individuals compared to patients with hypertrophic scars and keloids. Using sHLA-E as a diagnostic marker can differentiate between hypertrophic scars and keloids, which are traditionally considered pathological scars, and can also be used to assess the effectiveness of keloid treatment.

A method for preparation of biomass to support healing of hypertrophic scars and keloids is provided, which contains the steps: (a) culturing of mycelium of the filamentous fungus; (b) preparation of a pure culture of the filamentous fungus; (c) verification of the genus and species affiliation of the filamentous fungus; and (d) finalization of the biomass. The biomass produced in this way is deposited on a nanotechnology substrate in the form of a foil. Biomass according to this solution is suitable for supporting the healing of hypertrophic scars and keloids or to test medicinal substances intended for the skin.

The application discloses a kind of active delivery system of load ABPC-EVs and its application in the preparation of preventing or treating hyperplastic scar, belong to the field of biological medicine technology.The active delivery system of load ABPC-EVs described above is composed of ABPC-EVs and drug delivery system.The application utilizes ABPC-EVs as core biological active substance, by constructing active delivery system, is applied to the treatment and prevention of hyperplastic scar, can accurately intervene the abnormal metabolism of fibroblast, inhibits the pathological accumulation of collagen fiber, breaks through the dense tissue barrier caused by hyperplastic scar, realizes the accurate delivery of drug, and then realizes the physical flat of hyperplastic scar, color improvement and physiological reconstruction, solve the problems, such as lack of accurate physical-biological synergistic intervention, poor tissue remodeling quality and low bioavailability, in the prior art for treating hyperplastic scar, has great clinical application prospect.

The invention relates to the technical field of biological medicine manufacturing, in particular to a traditional Chinese medicine compound gel containing bioactive organic components and capable of synergistically repairing hypertrophic scars based on four-season qi and a preparation method of the traditional Chinese medicine compound gel. The compound gel is formed by mixing a bottle A base matrix and a bottle B four-season additive according to the ratio of 9: 1, the base substrate of the bottle A contains various bioactive organic components such as a salvia miltiorrhiza extract, asiatic acid, bioactive hirudin, perilla oil and the like; according to the four-season additive in the bottle B, corresponding traditional Chinese medicine extracts are selected according to seasons, the preparation method adopts a biotechnology process including supercritical COextraction, a biocompatibility nanometer co-grinding technology and other modern biotechnologies, the transdermal absorption rate of mineral components is remarkably increased, the anti-fibrosis effect is enhanced through a hirudin-perilla oil soluble synergistic system, and the anti-fibrosis effect is improved. The four-season differentiated formula realizes accurate repair of preventing wind evil in spring, clearing blood heat in summer, moistening dryness injury in autumn and dredging collaterals in winter.